{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:51:30Z","timestamp":1791460290613,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Grant of Jiangsu Commission of Health","award":["K2025042"],"award-info":[{"award-number":["K2025042"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0538800"],"award-info":[{"award-number":["2024ZD0538800"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>The optimal long-term antithrombotic strategy after left atrial appendage occlusion (LAAO) remains undetermined. The present study aimed to investigate whether half-dose rivaroxaban (10 mg daily) could better reduce silent cerebral embolic lesions (SCEs) and preserve cognitive function compared to antiplatelet therapy after successful LAAO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this investigator-initiated, prospective, multicenter, randomized controlled trial, patients with successful LAAO confirmed 45 days post-procedure were assigned 1:1 to half-dose rivaroxaban or antiplatelet therapy group. Diffusion-weighted magnetic resonance imaging and cognitive assessments were repeated at 90, 180, and 365 days after LAAO. The primary outcome was the patient-level incidence of any newly detected SCE during follow-up. Secondary outcomes included cognitive trajectories, SCE burden, and a composite of all-cause mortality, clinical thromboembolic events and major bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between December 2022 and February 2025, 164 patients were randomized. The patient-level incidence of new SCEs was significantly lower in the half-dose rivaroxaban group than in the antiplatelet therapy group [10\/82 (12.2%) vs. 26\/82 (31.7%); P = 0.005]. At 365 days, model-derived between-group differences favored the half-dose rivaroxaban group for both MMSE [2.56; 95% confidence interval (CI) 1.11-4.01; P &amp;lt; .001] and MoCA (2.67; 95% CI 1.07-4.26; P = .001) scores. The composite clinical outcome occurred in 2.4% of the half-dose rivaroxaban group vs. 11.0% of the antiplatelet therapy group (P = .057).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients eligible for oral anticoagulation after successful LAAO, rivaroxaban 10 mg daily significantly reduced SCEs and better maintained cognitive function compared with antiplatelet therapy, with numerically fewer composite clinical events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag734","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:02:11Z","timestamp":1788174131000},"source":"Crossref","is-referenced-by-count":0,"title":["Half-dose rivaroxaban vs antiplatelet therapy for preventing silent cerebral embolic lesions after left atrial appendage occlusion: the HALO-SCE trial"],"prefix":"10.1093","author":[{"given":"Kexin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Nantong University , Nantong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-0010","authenticated-orcid":false,"given":"Zhongbao","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University , Taizhou 225300 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4867-5341","authenticated-orcid":false,"given":"Hailei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zidun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-486X","authenticated-orcid":false,"given":"Minglong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]},{"name":"Department of Cardiology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University , Taizhou 225300 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-3308","authenticated-orcid":false,"given":"Weizhu","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026100807020153500_ehag734-B1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4244\/eijy19m08_01","article-title":"EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion\u2014an update","volume":"15","author":"Glikson","year":"2020","journal-title":"EuroIntervention"},{"key":"2026100807020153500_ehag734-B2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2408308","article-title":"Left atrial appendage closure after ablation for atrial fibrillation","volume":"392","author":"Wazni","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100807020153500_ehag734-B3","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa2517213","article-title":"Left atrial appendage closure or anticoagulation for atrial fibrillation","volume":"394","author":"Doshi","year":"2026","journal-title":"N Engl J Med"},{"key":"2026100807020153500_ehag734-B4","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1161\/circulationaha.125.077469","article-title":"Short-term anticoagulation versus dual antiplatelet therapy for preventing device thrombosis following left atrial appendage closure: the ANDES randomized clinical trial","volume":"152","author":"Rod\u00e9s-Cabau","year":"2025","journal-title":"Circulation"},{"key":"2026100807020153500_ehag734-B5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial","volume":"9","author":"Freixa","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026100807020153500_ehag734-B6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/ehjcvp\/pvaf078","article-title":"Antithrombotic strategies and DOAC dosing following left atrial appendage occlusion: a network meta-analysis","volume":"12","author":"Samaras","year":"2026","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026100807020153500_ehag734-B7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.amjcard.2017.03.253","article-title":"Changes in coagulation and platelet activation markers following transcatheter left atrial appendage closure","volume":"120","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026100807020153500_ehag734-B8","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1016\/j.jacc.2021.04.036","article-title":"Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation","volume":"77","author":"Lurie","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026100807020153500_ehag734-B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/jaha.124.037968","article-title":"Impact of silent cerebral embolism during and after left atrial appendage occlusion on long-term cognitive function","volume":"14","author":"Wang","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026100807020153500_ehag734-B10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1159\/000547304","article-title":"Half-dose anticoagulation versus antiplatelet therapy to reduce silent cerebral embolism after left atrial appendage occlusion (HALO-SCE study): rationale and design of a randomized clinical trial","volume":"55","author":"Wang","year":"2026","journal-title":"Cerebrovasc Dis"},{"key":"2026100807020153500_ehag734-B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/ejcts\/ezad074","article-title":"Surgical and percutaneous left atrial appendage intervention: silent cerebral embolism considerations","volume":"63","author":"Wang","year":"2023","journal-title":"Eur J Cardio-Thorac Surg"},{"key":"2026100807020153500_ehag734-B12","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/circulationaha.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials A consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2026100807020153500_ehag734-B13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2022.02.047","article-title":"Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation","volume":"79","author":"Freeman","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026100807020153500_ehag734-B14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/s0140-6736(09)61343-x","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"2026100807020153500_ehag734-B15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/circulationaha.110.976449","article-title":"Safety of percutaneous left atrial appendage closure results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry","volume":"123","author":"Reddy","year":"2011","journal-title":"Circulation"},{"key":"2026100807020153500_ehag734-B16","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026100807020153500_ehag734-B17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7326\/m14-0538","article-title":"Association between atrial fibrillation and silent cerebral infarctions A systematic review and meta-analysis","volume":"161","author":"Kalantarian","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026100807020153500_ehag734-B18","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1093\/eurheartj\/ehac020","article-title":"Silent brain infarcts impact on cognitive function in atrial fibrillation","volume":"43","author":"K\u00fchne","year":"2022","journal-title":"Eur Heart J"},{"key":"2026100807020153500_ehag734-B19","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular contributions to cognitive impairment and dementia A statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"key":"2026100807020153500_ehag734-B20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/eurheartj\/ehx579","article-title":"Less dementia with oral anticoagulation in atrial fibrillation","volume":"39","author":"Friberg","year":"2018","journal-title":"Eur Heart J"},{"key":"2026100807020153500_ehag734-B21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1055\/s-0039-1683429","article-title":"Incident atrial fibrillation, dementia and the role of anticoagulation: a population-based cohort study","volume":"119","author":"Field","year":"2019","journal-title":"Thromb Haemost"},{"key":"2026100807020153500_ehag734-B22","doi-asserted-by":"publisher","first-page":"E1309","DOI":"10.1212\/wnl.0000000000206748","article-title":"Oral anticoagulants and the risk of dementia in patients with nonvalvular atrial fibrillation A population-based cohort study","volume":"100","author":"Rahman","year":"2023","journal-title":"Neurology"},{"key":"2026100807020153500_ehag734-B23","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/eurheartj\/ehz304","article-title":"Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation","volume":"40","author":"Friberg","year":"2019","journal-title":"Eur Heart J"},{"key":"2026100807020153500_ehag734-B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41591-025-04101-y","article-title":"Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial","volume":"32","author":"Rivard","year":"2026","journal-title":"Nat Med"},{"key":"2026100807020153500_ehag734-B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1161\/circinterventions.119.008481","article-title":"Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure ADRIFT a randomized pilot study","volume":"13","author":"Duthoit","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2026100807020153500_ehag734-B26","doi-asserted-by":"publisher","DOI":"10.1161\/circinterventions.120.009039","article-title":"Short-term oral anticoagulation versus antiplatelet therapy following transcatheter left atrial appendage closure","volume":"13","author":"Asmarats","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2026100807020153500_ehag734-B27","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion","volume":"14","author":"Della Rocca","year":"2021","journal-title":"JACC Cardiovasc Interv"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag734\/70834056\/ehag734.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag734\/70834056\/ehag734.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag734\/70834056\/ehag734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:02:08Z","timestamp":1791457328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag734\/8772961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag734","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"ehag734"}}